Study to know role of Ayurveda medicines in Preventing COVID-19 infections

A clinical study to evaluate the role of Ayurveda medicines in Preventing COVID-19 infections

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/07/034606

Enrollment

5000

Registered

2021-07-05

Start date

Unknown

Completion date

Unknown

Last updated

2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: NF 2 Ayurevdic Propreitary Medicine: Dosage: 1gm (2 tablets of 500 mg) thrice a day with lukewarm water given half hour after meals for minimum of 3 months Control Intervention1: No pil

Eligibility

Inclusion criteria

Inclusion criteria: 1.People not vaccinated with any COVID Vaccine at the time of enrolment in the trial. 2.Age limit â?? 18 to 45 years, both Male & Female 3.Patients willing to give their consent to participate in the clinical trial

Exclusion criteria

Exclusion criteria: 1.People vaccinated with any Covid vaccine at any point of time before enrolment in the trial. 2.People with PCR proven Covid infections within the last 3 months 3.People taking other Ayurvedic/ Siddha medicines. 4.Patients with acute renal failure or Stage 4 CKD or Liver Failure (AST/ALT >5 times elevated) 5.Patients on Immuno-suppression therapy 6.Pregnant Women or lactating mothers

Design outcomes

Primary

Measure	Time frame
To study the effect of NF2 in the prevention of COVID-19 infectionsTimepoint: Baseline and 12 weeks	—

Secondary

Measure	Time frame
1.Symptom severity in infected cases by Modified Jackson score on Day1, 7 and 14. 2.Clinical status of infected cases on ordinal scale for Covid -19 at day 1, 7 and 14 Timepoint: Day1,7and14.	—

Countries

India

Contacts

Public ContactDrMRavi Kumar Reddy

Sree Ramachandra Health Services Pvt Ltd

ramheart@gmail.com9949033315

Outcome results